CRYSTAL TRASOLINE: Open Payments
NPI 1821318395 · GREENSBURG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,360 in 89 payments from 8 companies in 2025. Trend: 2023 $140 · 2024 $127 · 2025 $1,360
Food & beverage: $1,360
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 65 | $851 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $224 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Janssen Pharmaceuticals, Inc | 4 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Neurocrine BioSciences, Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, REXULTI, INVEGA SUSTENNA, FANAPT, INGREZZA, AUSTEDO XR, UZEDY.
Industry payments across PA — which companies pay providers there.
